It’s impossible for me to speculate on what is happening with Dr. Patterson’s paper without any inside information. As I’ve stated earlier though, the importance of the paper should not be underestimated.

We are a small company with no approved drugs pursuing FDA approval, approval by other countries, potential big pharma partnerships, raising capital, uplisting, etc. Anything we can do to increase credibility for Leronlimab is vital.

Perhaps the most important thing Dr Patterson’s paper would do is increase awareness in the scientific community, thus speeding up enrollment in cd12 which at last count is enrolling less than 1 patient
per day. A Dr.s enthusiasm for a drug is probably the most important factor in a patient (or their family) enrolling in a trial. Look at how Dr Recknor turbo charged cd10 enrollment for an example.

I know other papers are forthcoming but we have no idea when, or if they will be as impactful as Dr. Patterson’s. I would be extremely disheartened to learn if anyone at Cytodyn created any kind of a logjam in publication. That is simply cutting your nose to spite your (and the shareholders) face. I am patient and think we will eventually get approval with or without the published paper, but I would hope our company is doing everything possible to make that happen as quickly as possible.